The efficacy of Garcinia mangostana L. (mangosteen) pericarp as an adjunct with second generation antipsychotics for the treatment of Schizophrenia: A double- blind, randomized, placebo controlled trial.

James Cook University0 个研究点目标入组 80 人开始时间: 2011年8月25日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•1. Meet DSM-IV-TR criterion for schizophrenia
•2. Have current symptoms measured by PANSS score of over 54 or at least two items in the positive or negative items being greater than 2 or have a CGI-S score greater than 2 at baseline
•3. Capacity to consent
•4. Be stable on current medication regime for the past month
•5. Be utilising effective contraception if sexually active and of childbearing age
•6. Be aged 18-65 years on day of induction
•7. Be an outpatient currently prescribed a second generation antipsychotic medication
•8. Speak sufficient english so as not to require an interpreter
•9. Reside within a 100 kilometre radius of the Cairns, Grafton Street post office in Far North Queensland, Australia.

•1. Persons with a major comorbid medical illness that will restrict completion of the trial
•2. Persons with a current high risk of aggression
•3. Persons regularly taking up to 10 cups green tea on a daily basis
•4. Persons regularly taking at least 1000mg/day vitamin E supplements, however multivitamins are acceptable
•5. Persons with an allergy to mangosteen or rice flour
•6. Persons unable to comply with informed consent requirements or treatment protocol

发起方